Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Orsini

Cardiovascular Disease Little Rock, AR Medical Doctor

NPI 1609887124 CMS profile 299324

9501 Lile Dr Ste 600, Ste 600, Little Rock, AR 72205

Open in the dashboard

General payments

$4,344

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Orsini of Little Rock, AR is reported in the CMS Open Payments database as having received $4,344 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $785 33
2024 General $747 38
2023 General $580 29
2022 General $537 37
2021 General $682 53
2020 General $279 24
2019 General $733 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Orsini
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Alexander Orsini were reported at $785. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Alexander Orsini Cardiovascular Disease median Middle half National median
2019 $733 $450 $127–$1,392 $163
2020 $279 $242 $77–$751 $114
2021 $682 $335 $101–$1,037 $132
2022 $537 $395 $121–$1,211 $149
2023 $580 $443 $136–$1,283 $160
2024 $747 $450 $136–$1,323 $164
2025 $785 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,115 150 payments
  2. E.R. Squibb & Sons, L.L.C. $387 25 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $254 2 payments
  4. Boston Scientific Corporation $250 15 payments
  5. Janssen Pharmaceuticals, Inc $197 13 payments
  6. Amgen Inc. $166 10 payments
  7. Abbott Laboratories $158 7 payments
  8. Merck Sharp & Dohme Corporation $144 10 payments
  9. Abiomed $124 1 payment
  10. Pfizer Inc. $111 7 payments
  11. Other $438 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,344 268 payments
Products named General payments · program years 2019–2025
  1. ENTRESTO Cardiovascular $985 88 payments
  2. LEQVIO $758 37 payments
  3. ENTRESTO Cardiology/Vascular Diseases $268 16 payments
  4. CAMZYOS $256 15 payments
  5. JARDIANCE $254 2 payments
  6. XARELTO $197 13 payments
  7. VERQUVO $193 13 payments
  8. Repatha $166 10 payments
  9. ELIQUIS $131 10 payments
  10. Impella $124 1 payment
  11. Other $1,222 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

6,856

Median for Cardiology: 2,533

Drug cost

$1,070,782

Median for Cardiology: $485,213

Branded share of claims

29.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 663 $540,881
Entresto Sacubitril/Valsartan Brand 262 $209,512
Jardiance Empagliflozin Brand 224 $151,236
Xarelto Rivaroxaban Brand 131 $88,340
Repatha Syringe Evolocumab Brand 19 $9,860
Ranolazine Er Ranolazine Brand 101 $7,313
Brilinta Ticagrelor Brand 14 $6,209
Valsartan Generic 230 $5,073
Atorvastatin Calcium Generic 555 $5,044
Potassium Chloride Generic 214 $3,242

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$182,327

Medicare's payments for the services billed

Medicare patients

1,783

Average age 76

Services billed

4,435

999 women, 784 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 52%
Arthritis 52%
Atrial fibrillation 39%
Diabetes 34%
Heart failure 33%
Chronic kidney disease 31%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $217
$217 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $146
$146 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $131
$131 262 —
VERQUVO
  • Merck Sharp & Dohme Corporation $49
$49 — —
ELIQUIS
  • PFIZER INC. $17
  • E.R. Squibb & Sons, L.L.C. $17
$34 663 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record